Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures von Hallek, Michael, Al‐Sawaf, Othman

Volltext

High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies von Al-Sawaf, Othman

Volltext

Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations von Langerbeins, Petra, Giza, Adam, Robrecht, Sandra, Cramer, Paula, Tresckow, Julia, Al‐Sawaf, Othman, Fink, Anna Maria, Fürstenau, Moritz, Kater, Arnon P., Spek, Ellen, Niemann, Carsten Utoft, Cunha‐Bang, Caspar, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara

Volltext

Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2‐BCG): Final analysis of a multicenter, open‐label phase‐II‐trial von Cramer, Paula, Tresckow, Julia, Fink, Anna‐Maria, Robrecht, Sandra, Giza, Adam, Tausch, Eugen, Müller, Lothar, Knauf, Wolfgang, Zingerle, Matthias, Al‐Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Kreuzer, Karl‐Anton, Kneba, Michael, Wendtner, Clemens‐Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Volltext

Health‐related quality of life with fixed‐duration venetoclax‐obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial... von Al‐Sawaf, Othman, Gentile, Brittany, Devine, Jacob, Zhang, Can, Sail, Kavita, Tandon, Maneesh, Fink, Anna‐Maria, Kutsch, Nadine, Wendtner, Clemens‐Martin, Eichhorst, Barbara, Hallek, Michael, Fischer, Kirsten

Volltext

Nrf2 augments skeletal muscle regeneration after ischaemia-reperfusion injury von Al-Sawaf, Othman, Fragoulis, Athanassios, Rosen, Christian, Keimes, Nora, Liehn, Elisa Anamaria, Hölzle, Frank, Kan, Yuet Wai, Pufe, Thomas, Sönmez, Tolga Taha, Wruck, Christoph Jan

Volltext

Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia von Al‐Sawaf, Othman, Bahlo, Jasmin, Robrecht, Sandra, Fischer, Kirsten, Herling, Carmen D., Hoechstetter, Manuela, Fink, Anna‐Maria, Tresckow, Julia, Langerbeins, Petra, Cramer, Paula, Stilgenbauer, Stephan, Wendtner, Clemens M., Eichhorst, Barbara, Hallek, Michael, Goede, Valentin

Volltext

P623: MATCHING‐ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT... von Al‐Sawaf, Othman, Jen, Min‐Hua, Hess, Lisa, Zhang, Jiewen, Goebel, Benjamin, Pagel, John, Eyre, Toby

Volltext

Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL) von Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Günter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Goede, Valentin

Volltext

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities von Stamatopoulos, Kostas, Pavlova, Sarka, Al‐Sawaf, Othman, Chatzikonstantinou, Thomas, Karamanidou, Christina, Gaidano, Gianluca, Cymbalista, Florence, Kater, Arnon P., Rawstron, Andy, Scarfò, Lydia, Ghia, Paolo, Rosenquist, Richard

Volltext

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME‐LIMITED TREATMENT WITH ANTI‐CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2‐BAG, ‐BCG, ‐BI... von Yosifov, Deyan, Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Jebaraj, Billy, Mertens, Daniel, Ritgen, Matthias, Schilhabel, Anke, Kreuzer, Karl‐Anton, Maria Fink, Anna, Al‐Sawaf, Othman, Langerbeins, Petra, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Döhner, Hartmut, Stilgenbauer, Stephan, Cramer, Paula, Tausch, Eugen

Volltext

S145: VENETOCLAX‐OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6‐YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY von Al‐Sawaf, Othman, Robrecht, Sandra, Zhang, Can, Olivieri, Stefano, Chang, Yi Meng, Fink, Anna‐Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl‐Anton, Sivcheva, Liliya, Niemann, Carsten, Schwarer, Anthony, Loscertales Pueyo, Javier, Weinkove, Robert, Strumberg, Dirk, Kilfoyle, Allanah, Runkel, Eva, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, Fischer, Kirsten

Volltext

S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE‐BLIND, PLACEBO‐CO... von Langerbeins, Petra, Robrecht, Sandra, Nieper, Pascal, Cramer, Paula, Fürstenau, Moritz, Al‐Sawaf, Othman, Fink, Anna‐Maria, Kreuzer, Karl‐Anton, Vehling‐Kaiser, Ursula, Tausch, Eugen, Schneider, Christof, Müller, Lothar, Eckart, Michael, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Volltext

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia von Al-Sawaf, Othman, Zhang, Can, Jin, Hyun Yong, Robrecht, Sandra, Choi, Yoonha, Balasubramanian, Sandhya, Kotak, Alex, Chang, Yi Meng, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl-Anton, Chyla, Brenda, Paulson, Joseph N., Pallasch, Christian P., Frenzel, Lukas P., Peifer, Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, Fischer, Kirsten

Volltext

Venetoclax and obinutuzumab in chronic lymphocytic leukemia von Fischer, Kirsten, Al-Sawaf, Othman, Fink, Anna-Maria, Dixon, Mark, Bahlo, Jasmin, Warburton, Simon, Kipps, Thomas J., Weinkove, Robert, Robinson, Sue, Seiler, Till, Opat, Stephen, Owen, Carolyn, López, Javier, Humphrey, Kathryn, Humerickhouse, Rod, Tausch, Eugen, Frenzel, Lukas, Eichhorst, Barbara, Wendtner, Clemens-M., Stilgenbauer, Stephan, Langerak, Anton W., van Dongen, Jacque J.M., Böttcher, Sebastian, Ritgen, Matthias, Goede, Valentin, Mobasher, Mehrdad, Hallek, Michael

Volltext

Pirtobrutinib versus venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison von Al-Sawaf, Othman, Jen, Min-Hua, Hess, Lisa M, Zhang, Jiewen, Goebel, Benjamin, Pagel, John M, Abhyankar, Sarang, Davids, Matthew S, Eyre, Toby A

Volltext

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymph... von Al-Sawaf, Othman, Zhang, Can, Jin, Hyun Yong, Robrecht, Sandra, Choi, Yoonha, Balasubramanian, Sandhya, Kotak, Alex, Chang, Yi Meng, Fink, Anna Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Kreuzer, Karl-Anton, Chyla, Brenda, Paulson, Joseph N., Pallasch, Christian P., Frenzel, Lukas P., Peifer, Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael, Fischer, Kirsten

Volltext

Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial von Cramer, Paula, Tresckow, Julia V, Robrecht, Sandra, Bahlo, Jasmin, Fürstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J, Vehling-Kaiser, Ursula, Dürig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Böttcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael

Volltext

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Pro... von Fischer, Kirsten, Ritgen, Matthias, Al-Sawaf, Othman, Robrecht, Sandra, Tandon, Maneesh, Fink, Anna-Maria, Schilhabel, Anke, Stübig, Thomas, Brüggemann, Monika, Jiang, Yanwen, Schary, William, Eichhorst, Barbara F., Wendtner, Clemens-Martin, Tausch, Eugen, Kreuzer, Karl-Anton, Langerak, Anton W, Goede, Valentin, Böttcher, Sebastian, Stilgenbauer, Stephan, Kneba, Michael, Hallek, Michael

Volltext

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia von Al-Sawaf, Othman, Herling, Carmen Diana, Holtick, Udo, Scheid, Christoph, Cramer, Paula, Sasse, Stephanie, von Tresckow, Bastian, Tuchscherer, Armin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael, Frenzel, Lukas P

Volltext